MedTrace Logo

Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

NCT07706088 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-15

No results posted yet for this study

Summary

Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration.

Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.

Conditions

  • Neuropathy, Small Fiber
  • Diabete Mellitus

Interventions

DRUG

Tirzepatide 2.5mg weekly

tirzepatide will be initiated at 2.5 mg weekly and dose will be escalated to 7.5 mg weekly depending upon tolerance and changes in parameters from baseline as described as outcomes

DRUG

all standard of care to diabetic patient besides tirzepatide

diabetic patient will receive all standard of care beside tirzepatide

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-07-01
Completion
2028-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706088 on ClinicalTrials.gov